Literature DB >> 2522196

Physicians' acceptability of termination of pregnancy after prenatal diagnosis in southern France.

C Julian1, P Huard, J Gouvernet, J F Mattéi, S Aymé.   

Abstract

The acceptability of prenatal diagnosis for Down's syndrome has been extensively studied over the last 15 years but that of other pathologies remains largely unexplored. The main goals of this study were to approach physicians' opinions on six reasons for termination of pregnancy showing different deficiencies, i.e., Down's, Turner and Klinefelter syndromes, cystic fibrosis, spina bifida, and haemophilia, and to identify the origins of reserves. The influence of sociodemographic and professional characteristics of physicians on their opinions and attitudes during the consultation were studied. The data presented are based on information gathered in 1985 by a mailed questionnaire answered by 853 general practitioners, gynaecologists, obstetricians, and pediatricians in the Marseilles Genetic Centre's region. Stepwise logistic regression was used for the multivariate analysis. The results showed that 78 per cent of those answering favour termination of pregnancy for Down's syndrome and that only moral reticences were mentioned by the physicians opposed. Conversely, for haemophilia, only 21 per cent of the physicians considered this indication justified; those opposed were for the most part concerned that severity of illness did not justify termination of pregnancy. Overall, 33 per cent of physicians would voice their personal opinion on termination of pregnancy if so requested by consultees. Results on the influence of age and specialty evidenced their role on physicians' opinions. Indeed, 30 per cent of physicians opposed to pregnancy termination for one of the six fetal anomalies retained herein would modify their positions if diagnosis were possible in the first trimester of pregnancy.

Entities:  

Keywords:  Empirical Approach; Genetics and Reproduction; Abortion, Induced; Abortion, Legal; Age Factors; Behavior; Chromosome Abnormalities; Contraception; Contraceptive Usage; Data Analysis; Delivery Of Health Care; Demographic Factors; Developed Countries; Diseases; Ethics; Europe; Examinations And Diagnoses; Family Planning; Fertility Control, Postconception; France; Genetic Technics; Health; Health Personnel; Hereditary Diseases; Laboratory Examinations And Diagnoses; Mediterranean Countries; Method Acceptability; Multivariate Analysis; Neonatal Diseases And Abnormalities; Physicians; Population; Population Characteristics; Psychological Factors; Psychosocial Factors; Religion; Research Methodology; Sampling Studies; Studies; Surveys; Value Orientation; Western Europe

Mesh:

Year:  1989        PMID: 2522196     DOI: 10.1002/pd.1970090202

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  6 in total

1.  Down's syndrome screening is unethical: views of today's research ethics committees.

Authors:  T M Reynolds
Journal:  J Clin Pathol       Date:  2003-04       Impact factor: 3.411

2.  Adoption and fostering of babies with Down syndrome: a cohort of 593 cases.

Authors:  A C Dumaret; C De Vigan; C Julian-Reynier; J Goujard; D Rosset; S Aymé
Journal:  Prenat Diagn       Date:  1998-05       Impact factor: 3.050

3.  The ethics of antenatal screening: lessons from Canute.

Authors:  Timothy M Reynolds
Journal:  Clin Biochem Rev       Date:  2009-11

4.  The triple test as a screening technique for Down syndrome: reliability and relevance.

Authors:  Tim Reynolds
Journal:  Int J Womens Health       Date:  2010-08-09

5.  Prenatal and Obstetric Parameters of Late Terminations: A Retrospective Analysis.

Authors:  Anne Dathan-Stumpf; Julia Kern; Renaldo Faber; Holger Stepan
Journal:  Geburtshilfe Frauenheilkd       Date:  2021-07-13       Impact factor: 2.915

6.  Termination of pregnancy due to Thalassemia major, Hemophilia, and Down's syndrome: the views of Iranian physicians.

Authors:  Mehran Karimi; Mohammadmehdi Bonyadi; Mohhamad reza Galehdari; Soheila Zareifar
Journal:  BMC Med Ethics       Date:  2008-12-23       Impact factor: 2.652

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.